Gaia Gallo

2.3k total citations
82 papers, 1.3k citations indexed

About

Gaia Gallo is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, Gaia Gallo has authored 82 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Immunology, 33 papers in Dermatology and 33 papers in Rheumatology. Recurrent topics in Gaia Gallo's work include Psoriasis: Treatment and Pathogenesis (43 papers), Dermatology and Skin Diseases (32 papers) and Spondyloarthritis Studies and Treatments (21 papers). Gaia Gallo is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (43 papers), Dermatology and Skin Diseases (32 papers) and Spondyloarthritis Studies and Treatments (21 papers). Gaia Gallo collaborates with scholars based in United States, Germany and Canada. Gaia Gallo's co-authors include C. Paul, Russel Burge, Melinda Gooderham, Kim Papp, Mark Lebwohl, Andrew Blauvelt, Hany Elmaraghy, Chiara Rivoiro, David Oliver and Andrea Calvo and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of Investigative Dermatology and Journal of the American Academy of Dermatology.

In The Last Decade

Gaia Gallo

77 papers receiving 1.3k citations

Peers

Countries citing papers authored by Gaia Gallo

Since Specialization

Citations

This map shows the geographic impact of Gaia Gallo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gaia Gallo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gaia Gallo more than expected).

Fields of papers citing papers by Gaia Gallo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gaia Gallo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gaia Gallo. The network helps show where Gaia Gallo may publish in the future.

Co-authorship network of co-authors of Gaia Gallo

This figure shows the co-authorship network connecting the top 25 collaborators of Gaia Gallo. A scholar is included among the top collaborators of Gaia Gallo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gaia Gallo. Gaia Gallo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy 2025 ·Dermatology and Therapy ·(unknown), Thomas Bieber, Amy S. Paller, Lisa A. Beck, Masahiro Kamata, L. Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, J.Q. Del Rosso, Linda Stein Gold, (unknown), Martín Dossenbach, Gaia Gallo, (unknown), Marta Casillas, (unknown), (unknown), Raj Chovatiya	7
2	Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis 2025 ·Dermatology and Therapy ·Emma Guttman‐Yassky, (unknown), (unknown), (unknown), Brian J. Nickoloff, Christoph Preuß, Kimberly Siu, Chitra R Natalie, Gaia Gallo, (unknown), Kilian Eyerich, Mònica Aparici, Robert J. Benschop, Angela J. Okragly	1
3	Individual Clinical Response Trajectories to Lebrikizumab in Atopic Dermatitis: A Cluster Analysis 2025 ·SKIN The Journal of Cutaneous Medicine ·Andrew Blauvelt, Bruce Strober, Gaia Gallo, Yuxin Ding, Yun-Fei Chen, (unknown), (unknown), Linda Stein Gold, Jonathan I. Silverberg	0
4	Achieving Depth of Response in Skin Clearance and Itch Relief With Lebrikizumab is Associated With Minimal Impact of Atopic Dermatitis on Quality of Life 2025 ·SKIN The Journal of Cutaneous Medicine ·Raj Chovatiya, Eric L. Simpson, Tilo Biedermann, Leon Kircik, Vivian Y. Shi, Ignasi Figueras‐Nart, Marta Casillas, Gaia Gallo, Yuxin Ding, Hong Zhang, Evangeline Pierce, (unknown), Christian Vestergaard	0
5	53143 Clinical measures of improvement in atopic dermatitis are correlated with reductions in relevant biomarkers in patients treated with lebrikizumab 2024 ·Journal of the American Academy of Dermatology ·Emma Guttman‐Yassky, Zhe Sun, Brian J. Nickoloff, Chitra R Natalie, Gaia Gallo, (unknown), Kilian Eyerich, Mònica Aparici, Robert J. Benschop	1
6	Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment 2024 ·Dermatology and Therapy ·Jonathan I. Silverberg, Andreas Wollenberg, Linda Stein Gold, J.Q. Del Rosso, Gil Yosipovitch, Peter Lio, J.M. Carrascosa, Gaia Gallo, Yuxin Ding, (unknown), Marta Casillas, Evangeline Pierce, (unknown), Sonja Ständer	4
7	A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis 2023 ·Rheumatology and Therapy ·Bruce Kirkham, Alexander Egeberg, Frank Behrens, Andreas Pinter, Joseph F. Merola, (unknown), Gaia Gallo, (unknown), Rebecca Bolce, Christopher Schuster, Peter Nash, L. Puig	5
8	Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO) 2023 ·Frontiers in Medicine ·Stefano Piaserico, Elisabeth Riedl, Lev Pavlovsky, Ronald Vender, (unknown), (unknown), (unknown), Gaia Gallo, Christopher Schuster, Patrick M. Brunner	20
9	43054 The Psoriasis Study of Health Outcomes (PSoHO) in biologic-naïve and -experienced patients: A post-hoc analysis of patients receiving treatment according to US labels 2023 ·Journal of the American Academy of Dermatology ·Saakshi Khattri, Melinda Gooderham, Adam Reich, Charles Lynde, William N. Malatestinic, Catherine Reed, Alan Brnabic, (unknown), Gaia Gallo, Andreas Pinter	1
10	Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging 2022 ·Lara D. Veeken ·Walter P. Maksymowych, Rebecca Bolce, Gaia Gallo, (unknown), (unknown), David Sandoval, Mikkel Østergaard, Kurisu Tada, Xenofon Baraliakos, Atul Deodhar, Lianne S. Gensler	10
11	Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure 2022 ·Dermatology and Therapy ·C.E.M. Griffiths, Melinda Gooderham, Jean‐Frédéric Colombel, Tadashi Terui, (unknown), Gaia Gallo, (unknown), Andrew Blauvelt	17
12	Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study 2021 ·Arthritis & Rheumatology ·Laura C. Coates, Sreekumar Pillai, Hasan Tahir, Ivo Valter, Vinod Chandran, Hideto Kameda, Masato Okada, Lisa Kerr, (unknown), So Young Park, David H. Adams, Gaia Gallo, Matthew M. Hufford, Maja Hojnik, Philip J. Mease, Arthur Kavanaugh, (unknown)	16
13	649 Validation of the Optimal Psoriasis Assessment Tool (OPAT) as a method of assessing psoriasis severity and impact from physician and patient perspectives 2021 ·Journal of Investigative Dermatology ·C. Leonardi, Richard B. Warren, Kyoungah See, Russel Burge, Gaia Gallo, (unknown), (unknown), Claudia de la Cruz, (unknown), Bruce Strober	4
14	Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS ) 2020 ·British Journal of Dermatology ·Amy S. Paller, Marieke M.B. Seyger, (unknown), Jerry Bagel, Andreas Pinter, Jennifer Clay Cather, Stuart Keller, (unknown), Renata Gontijo Lima, Gaia Gallo, (unknown), Emily Edson‐Heredia, Lü Li, (unknown), Kim Papp, (unknown)	69
15	A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial* 2020 ·British Journal of Dermatology ·Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, C.E.M. Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, (unknown), Baojin Zhu, Kim Papp, (unknown)	73
16	Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis 2020 ·Arthritis Research & Therapy ·Bernard Combe, Proton Rahman, Hideto Kameda, Juan D. Cañete, Gaia Gallo, Noah Agada, Wen Xu, Mark C. Genovese	34
17	LB940 Ixekizumab versus guselkumab: 24-week clinical responses and 4-week gene expression data 2020 ·Journal of Investigative Dermatology ·Andrew Blauvelt, Andreas Pinter, Yayoi Tada, Hany Elmaraghy, Gaia Gallo, B J Nickoloff, L. Renda, (unknown), Lyn Guenther	2
18	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) 2019 ·Annals of the Rheumatic Diseases ·Maxime Dougados, James Cheng‐Chung Wei, Robert Landewé, Joachim Sieper, Xenofon Baraliakos, Filip Van den Bosch, Walter P. Maksymowych, Joerg Ermann, Jessica A. Walsh, Tetsuya Tomita, Atul Deodhar, Désirée van der Heijde, Xiaoqi Li, Fangyi Zhao, Clinton C. Bertram, Gaia Gallo, Hilde Carlier, Lianne S. Gensler	86
19	IXEKIZUMAB MAKES THERAPEUTIC THRESHOLDS POSSIBLE IN ACTIVE PSORIATIC ARTHRITIS PATIENTS: RESULTS FROM SPIRIT TRIALS 2018 ·Laura C. Coates, M. Elaine Husni, Éric Lespessailles, Lisa Kerr, Gaia Gallo	0
20	Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study 2015 ·BMJ Supportive & Palliative Care ·Simone Veronese, Gaia Gallo, Alessandro Valle, Chiara Cugno, Adriano Chiò, Andrea Calvo, Paola Cavalla, Maurizio Zibetti, Chiara Rivoiro, David Oliver	107

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact